此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

氢化可的松的调查研究

2026年9月10日 更新者:Neurocrine UK Limited

一项开放标签、部分随机、单剂量、交叉研究,以评估氢化可的松和 Infacort® 在健康成年男性志愿者中的 PK、口服生物利用度和与代谢参数的关系。

This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet and hydrocortisone intravenous (through the vein) injection.

The population who are eligible to take part in the study are healthy male volunteers, aged between 18 and 60 years of age.

研究概览

详细说明

The study will evaluate the normal physiology, PK and metabolism of cortisol, investigate the PK and bioavailability of cortisol from the test Infacort® Granules (hydrocortisone) and the reference hydrocortisone tablets and i.v injection in healthy adult male volunteers and explore the role of cortisol in the regulation of metabolic pathways.

研究类型

介入性

注册 (实际的)

14

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Merthyr Tydfil、英国、CF48 4DR
        • Simbec Research Limited

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).

  • Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))*2.

  • Subjects with no clinically significant abnormal serum biochemistry, haematology and urinalysis values within 14 days prior to Day 1 of Study Period 1.

  • Subjects with a negative urinary drugs of abuse screen, determined within 14 days prior to Day 1 of Study Period 1. A positive alcohol test may be repeated at the discretion of the Investigator.

  • Subjects with negative HIV and Hepatitis B and C results.

  • Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to Day 1 of Study Period 1.

  • Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.

  • Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example:

    • Oral contraceptive + condom
    • Intra-uterine device (IUD) + condom
    • Diaphragm with spermicide + condom
  • Subjects must be available to complete the study.

  • Subjects must satisfy a medical examiner about their fitness to participate in the study.

  • Subjects must provide written informed consent to participate in the study.

Exclusion Criteria:

  • A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
  • Receipt of regular medication within 14 days prior to Day 1 of Study Period 1 (including high dose vitamins, dietary supplements or herbal remedies).
  • Receipt of any vaccination within 14 days prior to Day 1 of Study Period 1.
  • Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
  • Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections).
  • Current or previous history of tuberculosis.
  • A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
  • A clinically significant history or family history of psychiatric disorders/illnesses.
  • A clinically significant history of drug or alcohol abuse.
  • Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
  • Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. The washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
  • Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to Day 1 of Study Period 1or have consumed any alcohol within the 48 hour period prior to Day 1 of Study Period 1.
  • Donation of 450ml or more of blood within the previous 3 months.
  • Subjects who smoke (or ex-smokers who have smoked within 6 months prior to Day 1 of Study Period 1).
  • Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Endogenous Cortisol

No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

其他:Dexamethasone

1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP

Challenge agent

其他名称:
  • 非IMP
实验性的:Infacort®

20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Multi-particulate granules

其他名称:
  • 英法考特
有源比较器:Hydrocortisone Tablet

20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Standard hydrocortisone tablets

其他名称:
  • 商业供应
有源比较器:i.v Hydrocortisone Injection

20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Standard hydrocortisone solution for intravenous injection

其他名称:
  • 商业供应

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum Serum Concentration (Cmax)
大体时间:Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Maximum serum concentration (Cmax)

Hourly from 0 to 24 hours
AUC0-t
大体时间:Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Area under the curve from 0-24 hours

Hourly from 0 to 24 hours

次要结果测量

结果测量
措施说明
大体时间
Adverse Events (AEs)
大体时间:Days 1-2 during each Study Period

Number of subjects with adverse events throughout the study.

Days 1-2 during each Study Period
Concentrations of Cortisol Binding Protein
大体时间:Blood samples on Day 1 and/or Day 2 of each Study Period

Cortisol protein binding under physiological conditions and after the administration of dexamethasone and hydrocortisone.

Blood samples on Day 1 and/or Day 2 of each Study Period
Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.
大体时间:Blood samples on Day 1 and/or Day 2 of each Study Period

A standardised mixed meal elevates blood glucose and provides a reproducible stimulation of insulin release. Lower levels of insulin secretion, whilst maintaining normoglycaemia would indicate enhanced insulin sensitivity and glucose disposal; higher insulin levels will reflect insulin resistance.

Blood samples on Day 1 and/or Day 2 of each Study Period
PK and Metabolism of Cortisol
大体时间:Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period

Blood: Serum cortisol under physiological conditions and after administration of dexamethasone and Infacort® Granules, Hydrocortisone Tablets and i.v Hydrocortisone Injection.

Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Girish Sharma、Simbec Research

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年10月1日

初级完成 (实际的)

2014年11月1日

研究完成 (实际的)

2014年11月1日

研究注册日期

首次提交

2013年10月6日

首先提交符合 QC 标准的

2013年10月9日

首次发布 (估计的)

2013年10月10日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月10日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅